Lantheus Medical Imaging Inc - Company Profile
Powered by 
All the data and insights you need on Lantheus Medical Imaging Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Lantheus Medical Imaging Inc Strategy Report
- Understand Lantheus Medical Imaging Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures and commercializes diagnostic imaging agents and products. The company offers commercial products including ultrasound contrast agent and medical radiopharmaceuticals in a range of imaging modalities. Its products include DEFINITY, TechneLite, Xenon 133, Neurolite, , Thallium-201, Cardiolite and Gallium-67. The company’s product pipeline include 1095 and LMI 1195. The company offers its products to nuclear physicians, internal medicine physicians, radiologists, technologists and sonographers, integrated delivery networks, hospitals, clinics and group practices. Lantheus Medical is headquartered in North Billerica, Massachusetts, the US.
Headquarters
United States of America
Address
331 Treble Cove Road, North Billerica, Massachusetts, 01862
Website
www.lantheus.com
Telephone
1 800 362 2668
No of Employees
612
Industry
Medical Equipment
Lantheus Medical Imaging Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Ultrasound Contrast Imaging Agent |
| DEFINITY |
| Medical Radiopharmaceuticals |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Perspective Therapeutics for the treatment of neuroendocrine tumors, and a right to co-fund the IND-enabling studies. |
| 2023 | Acquisitions/Mergers/Takeovers | In February, the company announced the acquisition of Cerveau Technologies. |
| 2023 | Regulatory Approval | In April, the company announced FDA grant of fast track designation for Lu-PNT2002 for the treatment of Metastatic Castration Resistant Prostate Cancer. |
Competitor Comparison
| Key Parameters | Lantheus Medical Imaging Inc | GE HealthCare Technologies Inc | RadNet Inc | AngioDynamics Inc | RedHill Biopharma Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Israel |
| City | North Billerica | Chicago | Los Angeles | Latham | Tel Aviv-Yafo |
| State/Province | Massachusetts | Illinois | California | New York | - |
| No. of Employees | 612 | 51,000 | 7,872 | 815 | 113 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mary Anne Heino | Director; President; Chief Executive Officer | Executive Board | 2015 | 63 |
| Robert J. Marshall Jr. | Chief Financial Officer; Treasurer | Senior Management | 2018 | 56 |
| Paul M. Blanchfield | Chief Operating Officer | Senior Management | 2022 | 42 |
| Andrea Sabens | Chief Accounting Officer | Senior Management | - | - |
| Daniel Niedzwiecki | General Counsel; Secretary; Chief Administrative Officer | Senior Management | - | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer